A Prospective Study of the Efficacy of Vitoss (Beta Tricalcium Phosphate) as a Bone Graft Substitute for Instrumented Posterolateral Lumbar Fusions

Marya, Shivan; Ariyanayagam, Timothy; Chatterjee, Bob; Toms, Andoni P.; Crawford, R. J.

doi:10.1016/j.spinee.2016.12.071

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitoss R (Orthovita, Inc. PA, USA), is a bestselling synthetic bone graft substitute composed of 100 nm β-tricalcium phosphate (β-TCP, Ca 3 [PO 4 ] 2 ) nanocrystals ( Figure 2) approved by the FDA in 2003 through 510(k) pathway; an approval mechanism for medical devices [139]. Vitoss is able to mimic the structure of cancellous bone (also known as spongy or trabecular bone) and can fill voids or gaps in the skeletal system.…”

Section: Vitoss Rmentioning

confidence: 99%

Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities

Farjadian

Ghasemi

Gohari

et al. 2018

Nanomedicine (Lond.)

474

213

View full text Add to dashboard Cite

There has been a revolution in nanotechnology and nanomedicine. Since 1980, there has been a remarkable increase in approved nano-based pharmaceutical products. These novel nano-based systems can either be therapeutic agents themselves, or else act as vehicles to carry different active pharmaceutical agents into specific parts of the body. Currently marketed nanostructures include nanocrystals, liposomes and lipid nanoparticles, PEGylated polymeric nanodrugs, other polymers, protein-based nanoparticles and metal-based nanoparticles. A range of issues must be addressed in the development of these nanostructures. Ethics, market size, possibility of market failure, costs and commercial development, are some topics which are on the table to be discussed. After passing all the ethical and biological assessments, and satisfying the investors as to future profitability, only a handful of these nanoformulations, successfully obtained marketing approval. We survey the range of nanomedicines that have received regulatory approval and are marketed. We discuss ethics, costs, commercial development and possible market failure. We estimate the global nanomedicine market size and future growth. Our goal is to summarize the different approved nanoformulations on the market, and briefly cover the challenges and future outlook.

show abstract

Section: Vitoss Rmentioning

confidence: 99%

Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities

Farjadian

Ghasemi

Gohari

et al. 2018

Nanomedicine (Lond.)

474

213

View full text Add to dashboard Cite

show abstract

Scaffolds and coatings for bone regeneration

Pereira

Cengiz

Silva

et al. 2020

J Mater Sci: Mater Med

110

View full text Add to dashboard Cite

Bone tissue has an astonishing self-healing capacity yet only for non-critical size defects (<6 mm) and clinical intervention is needed for critical-size defects and beyond that along with non-union bone fractures and bone defects larger than critical size represent a major healthcare problem. Autografts are, still, being used as preferred to treat large bone defects. Mostly, due to the presence of living differentiated and progenitor cells, its osteogenic, osteoinductive and osteoconductive properties that allow osteogenesis, vascularization, and provide structural support. Bone tissue engineering strategies have been proposed to overcome the limited supply of grafts. Complete and successful bone regeneration can be influenced by several factors namely: the age of the patient, health, gender and is expected that the ideal scaffold for bone regeneration combines factors such as bioactivity and osteoinductivity. The commercially available products have as their main function the replacement of bone. Moreover, scaffolds still present limitations including poor osteointegration and limited vascularization. The introduction of pores in scaffolds are being used to promote the osteointegration as it allows cell and vessel infiltration. Moreover, combinations with growth factors or coatings have been explored as they can improve the osteoconductive and osteoinductive properties of the scaffold. This review focuses on the bone defects treatments and on the research of scaffolds for bone regeneration. Moreover, it summarizes the latest progress in the development of coatings used in bone tissue engineering. Despite the interesting advances which include the development of hybrid scaffolds, there are still important challenges that need to be addressed in order to fasten translation of scaffolds into the clinical scenario. Finally, we must reflect on the main challenges for bone tissue regeneration. There is a need to achieve a proper mechanical properties to bear the load of movements; have a scaffolds with a structure that fit the bone anatomy. Graphical Abstract* Helena Filipa Pereira

show abstract